Hsbc Holdings PLC Invests $9.14 Million in Xenon Pharmaceuticals Inc. $XENE

Hsbc Holdings PLC acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 151,474 shares of the biopharmaceutical company’s stock, valued at approximately $9,143,000. Hsbc Holdings PLC owned about 0.16% of Xenon Pharmaceuticals at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Xenon Pharmaceuticals during the second quarter worth about $454,057,000. Holocene Advisors LP purchased a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter valued at approximately $56,637,000. Wellington Management Group LLP raised its stake in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after acquiring an additional 1,435,096 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Xenon Pharmaceuticals by 1,968.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock worth $38,650,000 after acquiring an additional 820,608 shares during the last quarter. Finally, Vestal Point Capital LP lifted its holdings in shares of Xenon Pharmaceuticals by 53.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after acquiring an additional 700,000 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on XENE. JPMorgan Chase & Co. lifted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a report on Wednesday, May 27th. Needham & Company LLC decreased their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. HC Wainwright restated a “buy” rating and set a $74.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, August 10th. Wall Street Zen raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $77.13.

Insider Activity

In related news, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director directly owned 1,455 shares in the company, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steven Gannon sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total value of $640,600.00. Following the transaction, the director directly owned 1,870 shares of the company’s stock, valued at $119,792.20. The trade was a 84.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 12,512 shares of company stock worth $774,088. Corporate insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock opened at $59.99 on Friday. The stock has a market capitalization of $5.80 billion, a P/E ratio of -12.66 and a beta of 0.62. The company has a 50 day moving average price of $63.18 and a 200 day moving average price of $56.39. Xenon Pharmaceuticals Inc. has a fifty-two week low of $35.60 and a fifty-two week high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same quarter in the previous year, the company earned ($1.07) EPS. On average, research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.